Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Efficacy of Ponatinib in Patients with Chronic Myeloid Leukemia with Resistant or Intolerant Chronic Phase, Accelerated Phase or Blast Phase and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with T315I Mutation

Next Previous
Trial Profile

Safety and Efficacy of Ponatinib in Patients with Chronic Myeloid Leukemia with Resistant or Intolerant Chronic Phase, Accelerated Phase or Blast Phase and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with T315I Mutation

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 01 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ponatinib (Primary)
  • Indications Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Therapeutic Use
  • Acronyms OITI

Most Recent Events

  • 25 Nov 2024 According to an Incyte Corporation media release, data from this study will be presented t the 2024 American Society of Hematology (ASH) Annual Meeting in San Diego.
  • 15 Jun 2023 Results (n=120) assessing the treatment patterns and outcomes, including safety and efficacy of ponatinib in chronic myeloid leukaemia patients, presented at the 28th Congress of the European Haematology Association.
  • 14 Dec 2021 Results (n=119) assessing the treatment patterns and outcomes, including safety and efficacy, in patients with CML treated in Italy since the approval of ponatinib, presented at the 63rd American Society of Hematology Annual Meeting and Exposition.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top